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Several peptides derived from viral proteins, VP7 and NS2 of bluetongue virus 
(BTV), were synthesized for an immunologic detection assay: distinguishing between 
bluetongue virus infected, vaccinated, and noninfected animals (ruminants) with dot blot 
analysis. The School of Veterinary Medicine, University of California, Davis, supplied 
the serum samples from 24 bovine, 18 caprine, 23 ovine. Another 205 bison serum 
samples were obtained in Utah. The serum samples of BTV-infected animals revealed 
detectable antibodies to both VP7 and NS2 peptides, whereas vaccinated animals only 
exhibited antibodies against VP7. Noninfected animals did not display antibody against 
either viral peptide. These data confirmed the agar gel immunodiffusion assay results 
determined by the Ross A. Smart Veterinary Diagnostic Laboratory at Utah State 
University. These tests showed that the synthesized peptides of VP7 and NS2 can be used 
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effectively in an immunological assay that can detect and determine whether animals 
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INTRODUCTION 
Export restrictions are placed on animals from countries m which bluetongue 
disease has been identified. Animals must be tested for the presence or absence of anti-
BTV antibodies before importation to these countries. Agar gel immunodiffusion assay is 
currently used for this testing. In this assay antibodies are detected primarily against one 
major viral protein: VP7. However, farmers have already used vaccine to protect their 
livestock from BTV infection. The most often used vaccines include live attenuated 
viruses, inactivated purified virus, and recombinant expressed BTV protein. These 
vaccination methods all generate antibodies against VP7. Therefore, when using the agar 
gel immunodiffusion assay to detect BTV infected animals, vaccinated animals will 
falsely appear positive. 
During BTV infection, BTV replicates inside animal cells and generates structural 
and nonstructural proteins. At the same time, infected animals produce antibodies against 
both BTV structural and nonstructural proteins. However, animals vaccinated with BTV 
vaccines, synthetic immunogens, or inactivated BTV proteins (which are incapable of 
replication) produce antibodies only against the immunogens but not antibodies against 
any of the nonstructural BTV proteins. Thus, I have hypothesized that the presence and 
absence of antibodies against the BTV nonstructural proteins could be employed to 
determine whether an animal is infected or vaccinated. 
In this study, I developed an immunoblot assay to distinguish between BTV 
vaccinated and infected animals. I have chosen the antigenic epitopes on VP7, the inner 
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core protein, and NS2, the nonstructural protein to recognize the presence or absence of 
antibodies against VP7 protein or NS2 protein. 
BACKGROUND REVIEW 
Bluetongue virus (BTV) is the causative agent of the bluetongue disease in 
domestic livestock (sheep, goats, cattle, camels, etc.) and wild ruminants (bison, white-
tailed deer, elk, pronghorn antelope, etc.) (Roy, 1989). It is a member of the genus 
Orbivirus in the family Reoviridae (Joklik, 1983). The name Orbivirus was derived from 
the Latin word "orbis" which means "ring" or "circle." This name was based on electron 
microscope of the doughnut-like appearance of viral particle capsomers (Borden et al., 
1971). 
Bluetongue Disease 
Bluetongue disease has been found in many areas all over the world (South 
Africa, Indian, Australia, and North America). In most cases, the BTV infection of sheep 
is subclinical or mild, and the infected sheep generally recover completely within a few 
weeks (Parsonson, 1990). The death rate of infected sheep normally ranges from 2 to 
30% (Erasmus, 1975). However, there have been several outbreaks that have caused 
high mortalities in sheep herds. One such example resulted in a 75% mortality rate in 
Portugal and Spain (Gorman, 1990). 
One of the first clinical signs of this disease is a high fever accompanied with an 
increased respiratory rate (Erasmus, 1975). Nasal discharge usually becomes 
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mucopurulent after a few days, and the tongue also becomes cyanotic. This blue 
discoloration of the tongue became the source of the name of this pathogen. 
BTV is a non-enveloped virus with concentric protein shells (Eaton et al., 1990). 
It has an icosahedral shape with a diameter of about 68-70 nm (Hyatt and Eaton, 1988). 
There are three morphologically distinct BTV particles: virions, cores, and subcore. The 
bluetongue virions can be converted to core particles by removing the layer of outer 
capsid proteins (VP2 and VP5). The cores are made up of subcore particles and the inner 
capsid proteins (VP3 and VP7). The subcore particles work like a skeleton and consist of 
BTV proteins VPl, 4, and 6 along with the viral genome segments (Huismans and 
Cloete, 1987). 
Virion Proteins and RNAs 
BTV has seven structural proteins (VP 1, 2, 3, 4, 5, 6 and 7) and four non-
structural proteins (NS 1, 2, 3 and 3A) found in the infected cells. They are the products 
of the ten double-stranded RNA genome segments which are named Ll, L2, L3, Ml, M2, 
M3, Sl, S2, S3, and S4 (L: large, M: medium, and S: small). 
The Sl segment is 1156 bp in length (Kowalik and Li, 1991). It has one open 
reading frame encoding the protein VP7 with 349 amino acids (Li and Yang, 1990). VP 
7, a major inner core protein, has a predicted molecular mass of 34,548 Da (Mertens et 
al., 1984). VP7 was determined to be surface accessible, even though it is a major inner 
core protein (Wang et al., 1996). It is extremely hydrophobic and possesses strong group 
specific determinants (Yu et al., 1988). Two linear epitopes of VP7 were identified and 
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conserved among the five U.S. BTV serotypes (Li and Yang, 1992). Site-specific and 
deletion mutants expressed in insect cells demonstrated that a single lysine residue 
located at residue 255, as well as the carboxyl terminus of VP7, were essential for 
formation of core particles (Yu et al., 1988). This suggested an important role for VP7 in 
viral morphogenesis. Immunogold analysis indicated that VP7 was not only the major 
component of the outermost layer of the inner core but was also attached to a framework 
of VP3 (Hyatt and Eaton, 1988). 
The surface of the core particle contains trimers of VP7 arranged in icosahedral 
symmetry. Immunoelectron microscopic studies showed that amino terminal half of the 
VP7 molecule was exposed on the surface of the intact virion and served as a serogroup-
reactive epitope (Eaton et al, 1991; Prasad et al., 1992). Studies of the crystal structure of 
VP7 revealed the presence of two distinct domains (Grimes et al., 1995). One domain 
contains the central portion of the polypeptide chain (residues 121-249) and forms a beta-
sandwich. This domain forms the outer surface of the core. The other domain is larger, 
containing residues 1-120 and 250-349, and is composed of alpha-helices and long 
extended loops. This domain is less external to the core and is presumed to interact with 
the underlying VP3 and with other trimers of VP7. 
VP7 was suspected to have a role in viral assembly. When the major inner core 
proteins, VP7 and VP3 were co-expressed in a baculovirus expression system, formation 
of core-like particles occurred (French and Roy, 1990). Formation of core-like particles 
will not occur if VP3 is expressed alone, indicating that the presence of VP7 is necessary 
for the core assembly. 
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In addition to its role in viral assembly, VP7 is a serogroup-specific antigen 
(Huismasns and Erasmus, 1981). When antibodies from infected animals are examined, 
there are antibodies directed against VP2, VP3, VP5 and VP7. However, the majority of 
antibodies are directed against VP7, suggesting that VP7 contains immunodominant 
antigenic epitopes. Two contiguous epitopes have been mapped and are located between 
residues #339-349 and 122-139 (Li and Yang, 1990). A third epitope was subsequently 
identified and located between residues #256-275 (du Plessis et al., 1994). Another 
epitope has recently been mapped at the N-terminus of VP7 between amino acid residues 
#30-48 (Wang et al., 1994). Further immunoelectron microscopy studies have indicated 
that this N-terminus epitope is the only epitope identified which is surface accessible 
(Eaton et al., 1991; Hyatt and Eaton, 1988; Wang et al., 1996). This suggests that VP7 
may interact not only with VP3, but also with the outer core proteins VP2 and VPS. 
Studies of the antigenic epitopes of VP7 have shown that they are distributed throughout 
the entire protein, not in a specific domain (Wang et al., 1996). 
The S2 gene contains one open reading frame that encodes for a non-structural 
protein consisting of 357 amino acids, the NS2 (Yang et al., 1992). The length of the S2 
gene is 1125 bp and the molecular mass of the NS2 protein is 40,999 Da in size 
(Grubman et al., 1990; Yang and Li, 1992). When the deduced amino acid sequence was 
examined, it shows that NS2 has a high concentration of lysine and a highly conserved 
hydrophophilic region at the carboxyl-terminus among five US BTV serotypes (Yang et 
al., 1992). 
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Immunoelectron microscopy using anti-NS2 antibodies has shown that NS2 is 
present mostly in the viral inclusion bodies, a virus specific structure found only in BTV 
infected cells, and is not associated with virions (Hyatt and Eaton, 1988; Thomas et al., 
1990). The expression of NS2 in a baculovirus expression system results in the formation 
of viral inclusion bodies (Thomas et al., 1990). 
The NS2 protein is the only virus-specific phosphorylated protein that can be 
identified in BTV-infected cells (Huismans and Bassoon, 1983; Huismans et al., 1987b; 
Thomas, et al., 1990), and it could be also phosphorylated in vitro (Yang and Li, 1993). 
NS2 has unique RNA binding activity. It binds only to single-stranded RNAs (ss-RNA), 
but not to the other forms of nucleic acids (Huismans et al., 1987a). This protein may 
have a role in the selection and condensation for the ten mRNA species during viral 
replication. Deletion mutagenesis of the S2 gene was performed to determine which part 
of the NS2 molecule is involved in ss-RNA binding (Bremer et al., 1992). Deletion of up 
to 130 amino acids from the C-terminus had no effect in the ability of NS2 to bind ss-
RNA. However, deletion of 40 amino acids from the N-terminus of the NS2 protein led 
to the loss of all the ss-RNA binding activity. Recent study further showed that three 
domains (residue positions 2 to 11, 153 to 166, and 274 to 286) have affinity for ssRNA. 
This affinity was partially reduced by removal of each of them but was totally lost by 
deletion of all three domains (Fillmore et al., 2002). This ss-RNA binding ability appears 
to be independent of phosphorylation (Thomas et al., 1990). 
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Justification and Objectives 
The objective of this project was to develop an immunological assay for the 
diagnosis of BTV infected animals. Because of the number of vaccines currently being 
used, it will be necessary to develop an assay which can distinguish between a vaccinated 
animal and an infected one. Animals infected with BTV carry antibodies directed against 
all of the proteins encoded by the viral genomic double-stranded RNA, which include 
both the seven structural and nonstructural proteins. On the other hand, vaccinated 
animals only produce antibodies against the viral proteins with which they have been 
vaccinated. Animals vaccinated with inactivated virus (cannot initiate infection), will 
only produce antibodies against structural proteins found in the virion. By combining the 
use of a structural protein (VP7) and a nonstructural protein (NS2) in an assay, I 
hypothesize that we will be able to determine whether an animal having anti-BTV 
antibodies has been vaccinated or infected with BTV. 
The thesis research for my Master Degree involved the use of two peptides 
synthesized in the multiple antigen peptide (MAP) format and derived from viral 
proteins, VP7 and NS2 of BTV, to detect if the animals were BTV-infected or BTV-
vaccinated. VP7 is also highly antigenic. The NS2 is a nonstructural protein that is only 
expressed when the viruses are replicating inside the host cells. In case of BTV-infection, 
infected animal will produces antibodies against all the viral proteins including VP7 and 
NS2. If the animals were vaccinated with inactivated viruses, there will be no infection 
and no production of the nonstructural proteins. Thus, BTV-vaccinated animal will have 
only anti-VP7 antibodies expressed. 
MATERIAL AND METHODS 
Prediction of Potential Antigenic Determination from Deduced 
Amino Acid Sequences of VP7 and NS2 
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The genomic (S 1 and S2) and their deduced amino acid sequences of VP7 and 
NS2 have been determined (Kowalik and Li, 1991; Yang et al., 1992). The potential 
antigenic epitopes and determinants of VP7 and NS2 were deduced from amino acid 
sequences with several computer programs that examined and analyzed (a) presence of 
ex-helices, ~-turns puff and loop structures; (b) distribution and ratio of hydrophilicity 
and hydrophobicity in different regions along the protein sequence; (c) protein 
hydropathic characteristics; (d) periodicity in protein hydrophobicity and hydrophobic 
moment; and (e) atomic mobility of sites in a protein. Once the potential epitopes were 
predicted and identified, synthetic peptides corresponded to these linear antigenic 
determinants were synthesized in the multiple antigenic peptide (MAP) format at the 
protein lab of the USU Biotechnology Center (Table 1). 
Polyclonal and Monoclonal Antibodies 
I used the following polyclonal and monoclonal antibodies previously made by 
Dr. Li: monoclonal antibody 45.5.1 specifically made against VP7m, polyclonal antibody 
#79 was against whole virus, and polyclonal antibody #67 was against NS2 peptide. 
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Immunoblot Analysis 
A dot-blot system was developed to test the sera obtained from bison, elk, goat, 
and deer. Gloves were worn to avoid cross contamination of the nitrocellulose membrane 
with bare hands. All the incubations were done at room temperature (RT). 
The 0.45-µm nitrocellulose membrane and 3MM filter paper were first wetted 
with distilled water and then with lX PBS buffer (5 min each). After the wetting, the 
membrane and filter paper were mounted with the 96-well apparatus (Bio-Rad) and 100 
µl of various peptide diluted solutions were loaded onto each well (concentration of stock 
solutions of peptide VP7 and NS2 was 1 mg/ml). The peptides were immobilized onto 
the membrane at room temperature for 2 hours. Then the apparatus was taken apart and 
the membrane was washed with lX PBS buffer three times (5 min each), with gentle 
rocking. After washing, the membrane was incubated in 10% Carnation Milk for 2 hours 
with gentle rocking. Washing steps were repeated three more times to remove the 
excessive and unblocked milk protein. 
The membrane was then cut into strips and each was incubated in 2 ml of the 
different dilutions of primary antisera (e.g., bovine, sheep, and bovine serum) for 2 hours 
with gentle rocking. Then the washing step in the last paragraph is repeated three times to 
remove unattached antibodies. The washed membrane was then incubated in 1 :5000 
dilution of the secondary anti-bovine antibody that was conjugated with Alkaline 
Phosphatase (goat anti-bovine IgG, 0.3 mg/ml in H20 and glycerol, Chemicon) for 2 
hours with gentle rocking. Washing steps were repeated three more times and distilled 
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water was used instead of lX PBS, since the substrate tablet used in the final color 
reaction step had the buffer substance of choice. 
One tablet of the BCIP/NBT Alkaline Phosphatase Substrate (SIGMA FAST™ 5-
Bromo-4-Chloro-3-Indolyl Phosphate/Nitro Blue Tetrazoluim Tablets) was dissolved in 
10 ml H2O. The development time was five minutes. After the substrate solution was 
removed, the membrane was rinsed with water, dried on the 3MM filter paper, and then 
stored and protected with a transparency cover for subsequent analysis. 
Electrophoresis Analysis 
The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was set up and run according to the protocol described by Laemmli (1970), using the 
Mini-Protein II Electrophoresis Cell (Bio-Rad). The 15% separating gel was composed 
of: 1.2 ml ddH2O, 2.5 ml 30% acrylamide/0.8% bisacrylamide solution, 1.3 ml of 4X 
gel separation buffer (1.5 M Tris-HCI, pH 8.0, and 0.4% SDS), 10 µl 20% ammonium 
persulfate, and 5 µl N,N,N' ,N'-tetramethylethylenediamine (TEMED). The separating 
gel mix was poured into the gel apparatus, overlaid with distilled water, and allowed to 
stand at room temperature until the gel polymerized (about fifteen minutes). The ddH2O 
cover was removed. The staking gel included: 970 µl ddH2O, 250 µl of 30% 
acrylamide/0.8% bisacrylamide solution, 420 µl of 4X gel staking buffer (500 mM Tris-
HCl, pH 6.8, and 0.4% SDS), 5 µl 20% ammonium persulfate, and 5 µl TEMED. The 
staking gel mixture was poured on top of the separating gel and the comb was inserted to 
create sample wells. After the gel was allowed to polymerize for 20 min, it was placed in 
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the gel apparatus which contained the reservoir running buffer (25 mM Tris-HCl, pH 8.3, 
0.2 M glycine, and 1 % SDS). The gel comb was removed from the gel and a small 
amount of loading buffer (20% glycerol, 2% SDS, lX staking gel buffer, 0.5% beta-
mercaptoethanol, 25 µg/ml bromophenol blue) was added to each well to aid in 
visualizing the wells. Each well was rinsed out gently several times with reservoir buffer 
to remove any gel fragments. Samples with 30-50 µl of loading buffer was heated in a 
boiling water bath for five minutes and then loaded into the wells. The gel was 
electrophoresed for one hour at 200 V. The mini gel apparatus was disassembled and the 
gel was stained with Commassie Blue staining solution (50% methanol, 10% glacial 
acetic acid, and 2.5% Commassie Brilliant Blue) overnight with gentle rocking. The gel 
was then be destained three times using 50% methanol and 10% glacial acetic acid. 
Immunoblotting and Detection 
The immunodetection method used was described in the Promega technical 
manual (Promega Protocols and Applications Guide, 1991). By using Western Blot 
buffer (20% [v/v] methanol, 25 mM Tris-HCl, pH 8.3, and 0.192 M glycine), viral 
proteins and or peptides separated in a 10% SDS-PAGE gel were sandwich-blotted onto 
two nitrocellulose membranes (Tow bin et al., 1979). The membranes were removed and 
"blocked" using 10 ml of 1 % (w/v) BSA in TBST (0.1 M Tris-HCl, pH 7.5, 0.9% [w/v] 
NaCl, and 0.1 % [v/v] Tween-20) for 1 hour at room temperature. After the BSA solution 
was removed, 10 ml of lX TBST containing the primary antibody sera, such as #79 and 
#45.4.1, was added to the membrane. The membranes were then incubated for one hour, 
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and washed three times in TBST, 30 mm each. The secondary antibody, alkaline 
phosphatase-conjugated goat anti-rabbit antibody, was diluted 1: 10,000 with TBST and 
then added to the membranes, which were again incubated for one hour. Following this 
incubation, the membranes were washed three times for 30 min each in TBST to remove 
unattached secondary antibodies. Finally, 10 ml of freshly prepared substrate solution 
(0.1 M Tris-HCl, pH 9.5, 0.1 M NaCl, 5 mM MgCh, p-nitro blue tetrazolium chloride 
[150 µg/ml], and 5-bromo-4-chloro-3-indoyl phosphate p-toluidine salt [75 µg/ml]) was 
added to the membranes that were incubated between 5-10 min for color development. 
The membranes were then washed three times with ddH20 to stop the color reaction. 
RESULTS 
Determining Optional Conditions of Testing VP7 and NS2 Peptides as 
Substrate for Immunoblot Assay 
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Tested peptides included three VP7 peptides derived from three different epitope 
locations on the VP7 protein and one on the NS2 protein. PBS and TBS buffers were 
tested. Both had similar effect on immunoblot. PBS was chose for later experiments due 
to simplicity of its making and consistence with previous work. ELISA was also tested. 
However, its absorbance gradient in correspondence with the amount of peptides was not 
as good as the immunoblot. So I just used the immunoblot assay for my rest of the 
testing. 
At the same time, different concentrations and incubation times were also 
optimized for peptides, antibodies, and sera. Second antibodies were tested also to make 
sure the conjugated enzyme (i.e., alkaline phosphatase) was active and the second 
antibodies could successfully and specifically recognized antibodies from bison (i.e., 
buffalo), caprine (i.e., goat), and other tested animals. 
Since there were no commercial secondary antibodies against bison serum, we 
tested those made for bovine serum to show that the secondary antibodies against bovine 
also reacted with bison serum but not with rabbit, ovine, elk, and caprine (Figure 1). 
Polyclonal antibodies of #67 and #79 were made against NS2 and VP7 proteins, 
respectively. Monoclonal antibody 45.5.1 was against VP7m. In Figure 2, NS2 peptide 










2X dilution of sera 1: 10 
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14 
3 4 5 6 7 8 
1:1280 
Fig. 1. Interaction of anti-bovine secondary antibody with different animal sera. Rabbit 
sera: #79, 67, and 68; ovine serum: YV1003; bison serum: buffalo #1; bovine serum: 
BK2015; Elk serum: CU2004; and caprine serum: BM2018. Dilution of anti-bovine 
secondary antibody was 1 :30,000. Note that at these dilutions only bovine and bison 
interacted with the anti-bovine secondary antibody. Also note the weaker interaction with 
bison when compared with bovine. 
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with different NS2 peptide concentrations. When NS2 peptide was used as test substrate 
for testing sera from bison, ovine, bovine, caprine, it produced similar results as NS2 
proteins. We concluded that this specific amino acid sequence is an antigenic epitope on 
NS2 protein. 
On the contrary, the VP7m peptide did not give us the result we anticipated. It 
showed positive results with 45.5.1 monoclonal antibody. However, polyclonal antibody 
#79 didn't recognize the VP7m peptide (data not shown). VP7m was also tested negative 
with serum samples from bison, ovine and caprine, which were determined as positive for 
BTV infection using VP7 and NS2 proteins. 
To further prove that VP7m peptide is not an ideal antigenic epitope and NS2 
peptide is, Western Blot was used (Figure 3 and 4). On the blots, polyclonal antibody #67 
could recognize both NS2 fusion protein and peptide; polyconal antibody #79 could only 
bind to VP7 protein but VP7m peptide; monoclonal antibody 45.4.1 could only bind to 
VP7m but not VP7 protein. All of the above results indicated that the VP7m was not a 
significant immunodominant antigenic epitope on VP7 protein. 
Identification of Strong Antigenic Epitope on VP7 Protein 
To investigate and map the potential antigenic epitopes on VP7 proteins, three 
more peptides were synthesized. Their sequences and locations on VP7 proteins were 
shown in Table 1. Immunoblot method was used to identify their antigenic features. The 
results indicated that VP7c and VP7n were both antigenic epitopes and VP7k was not 
(figure 5). 







Peptides (µg) 0.1 0.00625 (-) 0.1 
VP7m 
B) Interaction ofNS2 peptide with #67 polyclonal antibody 
tlf,7 
NS2 Peptide (µg) 0.1 0.00625 (-) 
NS2 
C) Interaction ofVP7m peptide with 45.5. l monoclonal antibody 
45.4.1 
VP7m Peptide (µg) 0.1 0.00625 (-) 
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0.00625 (-) 
Fig. 2. Interaction of VP7m and NS2 peptides with bison sera and 45.4.1 monoclonal 
antibody and #67 ployclonal antibody. The antibodies of #67 and 45.5.1 were 1 :400 
diluted and bison sera were 1 :200 diluted. Note that VP7m peptide could only be 
recognized by its monoclonal antibody 45.5.1 but not bison sera and NS2 peptide could 
be recognized by both of its polyclonal antibody #67 and bison sera. 
A) #67 polyclonal antibody 
Marker VP7 Protein NS2 Protein VP7m NS2 
◄ .. ◄ .. 




B) #79 polyclonal antibody 
Peptides 
VP7m NS2 NS2 Protein 'f P7 Protei~ Marker 





Fig. 3. Interaction of VP7 and NS2 proteins and peptides with #67 and #79 polyclonal 
antibodies on Western Blot. Note that the NS2 peptide could be recognized by #67, 
which at the same time interacted with NS2 protein. Also note that the VP7m peptides 
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Fig. 4. Interaction of VP7 and NS2 proteins and peptides with 45.4.1 monoclonal 
antibody on Western Blot. Note that 45.5.1 monoclonal antibody could not recognize 
VP7 protein but VP7m peptide. 
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Different combinations of the above four peptides were also tested: VP7n and 
VP7c, VP7n and VP7m, VP7c and VP7m, and VP7m and VP7k. The results were similar 
to or worse than those of VP7n. VP7n peptide was used for later tests on animal sera due 
to its stronger signals than that of VP7c. 
Testing of Robot-loaded Peptides and Specificity of Assay 
Systhesizing peptides by a peptide instrument can provide us pure product in a 
very short time. The same idea was applied to loading peptides on nitrocellulose 
membrane. However, the results were not satisfying. The robot-loaded VP7n peptides 
showed negative results for the same serum samples that was tested positive with hand-
loaded VP7n peptides (data not shown). 
The possibility of the existence of VP7n or NS2 peptides on proteins other than 
VP7 and NS2 protein were tested with the protein-to-protein BLAST program on the 
website of National Center for Biotechnology Information, which is 
http://www.ncbi.nlm.nih.gov. There were no same peptide sequences found on the 
proteins of any other proteins. 
Test of Different Animal Sera 
Finally, VP7n and NS2 peptides were used to test all the samples from bison, 
bovine, ovine, and caprine. In Figures 6 and 7, results of testing two serum samples from 
each species were shown. There were 195 bison serum samples that were tested at the 
Ross A. Smart Veterinary Diagnostic Laboratory at USU with the use of agar gel 
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immunodiffusion. Only four samples were negative (#58, 102, 103, and 145) and all the 
others were positive for BTV antibodies. In the immunoblot assay we developed in this 
study, 46 serum samples tested positive to VP7m peptide but negative to NS2, which 
were classified as samples from vaccinated animals and the rest were positive for BTV 
antibodies. A summary of all the bison sera tested in the study is showed in Table 2 
(listed in Appendix A). 
Twenty-three ovine serum samples were also tested and they all showed the 
pattern of vaccination: positive for VP7n peptide and negative for NS2 peptide (listed in 
Table 3 of Appendix A). Five out of 18 caprine samples were tested positive for the BTV 
infection and the rest 13 samples were found to be vaccinated (Table 5 of Appendix A). 
The five bovine serum samples, listed in Table 4 of Appendix A, were obtained 
from California. All these samples were positive for both VP7n and NS2 antibodies by 
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Fig. 5. Antigenic features of VP7c, VP7n, and VP7k peptides. The peptides were 1 :2 
diluted and #79 polyclonal antibody was added in 1 :400 dilution. Note that both VP7n 
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NS2 Peptide (µg) 1 0.0625 (-) 
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Fig. 6. Immunoblot analysis of bison and ovine test sera using VP7n and NS2 peptides. 
All tested sera were diluted 1 :200 and peptides were 1 :2 diluted. Note that Bison 57 
showed positive for both peptides; Bison 58, YV1003, and YV1006 were positive for 




















NS2 Peptide (µg) 1 0.0625 (-) 
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Fig. 7. Imrnunoblot analysis of bovine and caprine test sera using VP7n and NS2 
peptides. All test sera were diluted 1 :200 and peptides were 1 :2 diluted. Note that 
BK2007, BK20012, BM2018, and BM2020 were all positive for both peptides. 
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DISCUSSION 
The basic idea of my thesis is to develop an assay that can identify and 
differentiate BTV-infected livestock from vaccinated ones. However, since I am using 
peptides that are derived from viral proteins, the reaction of these peptides with animal 
sera must be optimized and this can also shed light on the immunogenicity of predicated 
epitopes in vivo. 
Diagnostic Assay of BTV 
Export restrictions are placed on the countries in which bluetongue disease has 
been identified. United States is one of them (Gibbs, 1983). Animals imported to or 
exported from US must be tested for the presence or absence of anti-BTV antibodies. 
Agar gel immunodiffusion assay is mostly used and antibodies detected in the assay are 
mainly these against VP7. At the same time, in order to prevent BTV, some farmers in 
the US have already adopted some vaccination methods. These methods include live 
attenuated viruses, inactivated purified virus, and recombinant expressed BTV protein 
(Brown et al., 1991). However, these vaccination methods all generate antibodies against 
VP7. Thus all the vaccinated animals will be classified as infected animals when current 
agar gel immunodiffusion assay is used. This may make farmers reluctant to immunize 
their animals against BTV. 
During BTV infection, animals produce antibodies against both BTV structural 
and nonstructural proteins. However, current BTV immunogens are made up of structural 
proteins. Thus, animals vaccinated with BTV vaccines, synthetic immunogens, or 
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inactivated BTV proteins (which are incapable of replication) produce antibodies only 
against the immunogens but not antibodies against any of the nonstructural BTV proteins, 
such as NS 1, NS2, NS3/3A, since there is no viral replication in the BTV-vaccinated 
animal. Thus, we have hypothesized that the presence and absence of antibodies against 
the BTV nonstructural protein (e.g., NS2) could be employed to determine whether an 
animal is infected or vaccinated. 
In our lab, Mary Wise previously developed a BTV diagnostic assay usmg 
heterologouly expressed recombinant structural protein VP7 and nonstructural protein 
NS2. The major inner core protein, VP7, was chosen because of its high immunogenicity, 
and NS2 was chosen because of its abundant production in early infection. 
In my assay, peptides derived from epitopes of VP7 and NS2 were used instead of 
recombinant protein VP7 and NS2. Several advantages of peptides are (1) peptide is easy 
to synthesize at low cost and store, (2) their quantities are easy to determine, (3) the 
consistence and optimization of the test with peptides is easier to achieve, and ( 4) the test 
with peptides is easier to carried out in field. 
We have used these peptides to determine if there were antibodies against BTV 
present in 241 different animal serum samples. The secondary antibody used for our 
detection was an anti-species AP-conjugated antibody. We found that anti-bovine serum 
was effective in detecting bison sera. Of the 195 bison serum samples tested, 149 tested 
positive for BTV infection and the rest of the samples tested positive for VP7n peptide 
but negative for NS2. The determined infection samples were less than that in Mary 
Wise's research using VP7 and NS2 proteins. The reason might be that the antibodies 
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against NS2 protein in serum samples could not recognize the NS2 peptide in our assay 
as well as the NS2 recombinant protein in Mary Wise's research. Five bovine serum 
samples were tested positive for BTV infection. Twenty-three ovine serum samples were 
also tested and they all showed the pattern of vaccination: positive for VP7n peptide and 
negative for NS2 peptide; five out of 18 caprine samples were tested positive for the BTV 
infection and the rest 13 samples were found to be vaccinated. 
Compared to Mary Wise's results, the NS2 peptide was less likely to be 
recognized by animal sera from four different species: bison, bovine, ovine, and caprine. 
One the contrary, the VP7n peptide reacted with different sera with high positive rate. 
Since the NS2 peptide is the essential to identify the vaccinated animals from infected 
ones, NS2 epitopes other than the current one might give us better candidates to increase 
the accuracy of this assay. 
However, simplicity of working with peptides appears to be the big advantage of 
this diagnostic assay. We tried to use robotic machine to load the peptides onto the 
nitrocellulose membrane, which could make many blots in a very short time, much faster 
than hand-made. But machine-made blots could not react well with animal sera. The 
reasons might be the nitrocellulose membranes were not wetted before the peptides were 
loaded by the machine. If we could solve this problem, we would achieve more 
consistence and efficiency in the tests. 
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Immunogenicity of VP7 and NS2 Epitopes 
I have used and investigated four peptides derived from VP7 protein and only two 
of them are recognized by antisera. Since these peptides were located and mapped by 
computational tools, the results can help us to understand the nature of the interactions 
between viral antigens and the immune system, which is crucial to understanding the 
mechanisms utilized by vertebrates to clear viral infection and to development of 
effective immunization strategies for protection against viral diseases. 
The pioneer work of using synthetic peptides in the study of immunization against 
virus was done in 1960s. A peptide synthesized correspondingly to the carboxyl terminal 
fragment of the coat protein of tobacco mosaic virus would elicit the formation of virus-
neutralizing antibodies in rabbits and also neutralizing antibody (Anderer and 
Schlumberger, 1966). Later on similar observation was found m bacteriophage: a 
fragment of 21 amino acids of the coat protein of MS2, an RNA-containing 
bacteriophage, elicited antibody that reacted with the intact virus particle; subsequent 
addition of the anti-species antibody neutralized the infectivity of the virus (Fuchs et al., 
1973; Langebeheim et al., 1976). The synthetic peptide corresponding in sequence to this 
fragment elicited a similar response. 
Through previous study in Dr. Li's lab, several immunodominant antigenic 
epitopes of VP7 have been identified (Li and Yang, 1990). A combination of polyclonal, 
monoclonal, and oligoclonal antibodies were used in Western blot to analyze intact VP7 
proteins and their proteolytic fragments of five bluetongue viruses found in the United 
States. Two linear immunodominant antigenic determinants were located and identified. 
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The carboxyl terminus of the viral protein was mapped by polyclonal antibody. Its 
sequence is L TRAIARAA YV (residues 339 through 349), which is dubbed in my assay 
is VP7c. The second epitope (ARQPYGFFLETEETFQPGR) was located by both 
monoclonal and oligoclonal antibodies. It was mapped between residues 121 and 140. 
We call it VP7m. These epitopes were highly conserved among the VP7 proteins of all 
five U.S. BTV (Li and Yang, 1990). 
In our research, VP7k (DKTLNQYPALTAE, residues from 254-266) was 
applied. This fragment is in the region spanning amino acids 255-274, which was mapped 
by two monoclonal antibodies by using synthesized peptides and filamentous phage 
library (du Plessis et al., 1994). A pentapeptide, QYPAL, and a hexapeptide, QYPALT, 
(amino acids 259-264), preferentially bound by both monoclonal antibodies. Residues Q 
and P were critical for recognition. The QYPALT antigenic region may not be ideally 
suited to this purpose because of its potential for serological cross-reactivity with an 
epitope on epizootic hemorrhagic disease virus. 
The sequence of RYNGLTLRGVTMR between residues amino acid 37 to 52 was 
synthesized and named VP7n, since the N-terminus of the VP7 molecule was proved to 
be oriented toward the surface of the virus (Wang et al., 1994). It is worth noting that the 
amino acid sequence from residue 21 to residue 54 is absolutely conserved in all 
sequenced BTV VP7 genes, including the Australian BTV-15 VP7 (Wang et al., 1994). 
Our result shows that the VP7c and VP7n peptides can be recognized by animal 
serum and VP7m and VP7k were not. We predict that N and C termini of VP7 are 
exposed to the host immune system and trigger large amount of antibodies against these 
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two epitopes. The residues on the locations of VP7m and VP7k are not on the viral 
surface. However, if they are on the surface, they are not the dominant epitopes. So our 
assay also gives light on the location and structure of VP7 on the virus. 
As for NS2 peptide, the NS2 protein is very immunogenic. It was reported that 
antibodies against the NS2 protein could be found in animals immunized purified BTV 
virions. Since our lab previously had reported that synthetic peptides could mimic the 
functions of the intact protein (Hayama and Li, 1994; Hwang et al., 1993), we were not 
surprised to find that NS2 peptide had affinity to antibodies in animal sera. 
We have developed an assay that applies easily quantified and delivered material: 
peptide, which has considerable potential for use in the field. With the help of this assay, 
people can determine if an animal has been infected or been vaccinated before export. 
Similar assay can be carried out in basic immunology research, such as determining the 
innocuity of inactivated vaccines, detecting viral replication, and measuring the 
protection against virulent BTV after vaccine potency trials. Thus, this assay could be 
potentially valuable to both the livestock industry and immunology research. 
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Appendix A: Tables 
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Table 1. Peptides used in the development of the diagnostic assay 
Amino Acid Peptide 
Peptide Name Position Peptide Sequence Source 
VP7c 339-349 LTRAIARAA YV VP7 
VP7k 255-266 DKTLNQYPALTAE VP7 
VP7n 38-50 RYNGLTLRGVTMR VP7 
VP7m 122-140 ARQPYGFFLETEETFQPGR VP7 
NS2 153-166 DIRELRQKIKNERE NS2 
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Table 2. Results of 195 bison sera testing using the BTV diagnostic assay 
Serum# Results* VP7n Peptide NS2 Peptide 
1 I +++ ++ 
2 I +++++ ++++ 
3 I ++++ ++ 
4 I +++++ + 
5 I +++++ + 
6 I ++++ ++ 
7 I ++++ ++ 
8 I ++++ ++++ 
9 I +++++ + 
11 I ++++ +++ 
12 I +++++ +++ 
13 I +++ ++++ 
14 I ++++ +++ 
15 I +++ +++ 
16 I ++++ ++ 
17 I ++++ +++ 
18 I ++++ +++ 
19 I +++ + 
20 V +++ 
21 I ++++ ++ 
22 I +++ + 
23 I +++ +++ 
24 I +++ +++++ 
25 I ++++ +++++ 
26 I +++ +++ 
27 I ++++ ++++ 
28 I +++ ++ 
29 I ++++ + 
30 I +++ + 
31 I +++ +++++ 
32 I +++ +++++ 
33 I ++++ +++++ 
34 I ++++ +++++ 
35 I ++++ ++++ 
36 I +++ + 
37 I ++ ++++ 
38 I +++ ++++ 
39 I +++ +++++ 
40 I ++++ ++++ 
41 I +++ ++ 
42 I ++++ +++++ 
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Serum# Results* VP7n Peptide NS2 Peptide 
43 I ++++ ++ 
44 I ++++ ++ 
45 I ++++ ++ 
46 I ++ +++ 
47 I +++ +++ 
48 I ++++ ++ 
49 I ++ +++ 
50 I ++ ++ 
51 I ++ + 
52 V ++ 
53 I ++ ++++ 
54 I ++ +++++ 
55 I ++++ +++ 
56 I +++++ ++++ 
57 I +++++ +++++ 
58 V +++++ 
59 I ++++ + 
60 I ++++ ++ 
61 I +++++ + 
62 I ++++ ++ 
63 I +++++ + 
64 I +++++ + 
65 I +++++ ++ 
67 I +++++ ++ 
68 V +++++ 
69 I +++++ + 
70 I +++++ + 
71 I +++++ +++++ 
72 I +++++ +++++ 
73 I + +++++ 
75 I ++++ + 
76 I +++++ ++ 
77 I +++++ + 
78 I +++++ +++ 
79 V +++++ 
80 V ++++ 
82 V +++++ 
83 V ++++ 
84 I ++++ ++ 
85 I +++++ +++ 
86 I +++++ ++ 
87 I ++++ + 
89 I +++++ +++++ 
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Serum# Results* VP7n Peptide NS2 Peptide 
90 I +++++ +++++ 
91 I ++++ +++++ 
93 I ++++ ++++ 
94 V ++++ 
95 I +++++ + 
97 I ++++ +++ 
98 I +++++ ++++ 
99 I ++++ +++ 
100 I +++++ +++ 
101 V +++++ 
102 V +++++ 
103 I +++++ +++ 
104 I +++++ ++ 
105 I ++++ ++++ 
109 I +++++ +++ 
110 I +++++ +++ 
112 I +++++ +++ 
116 V +++++ 
117 V +++++ 
118 V +++++ 
119 V +++++ 
120 V +++++ 
121 V +++++ 
122 I +++++ +++++ 
123 I +++++ ++++ 
124 I +++++ ++ 
125 I +++++ + 
126 I +++++ + 
127 V +++++ 
128 V +++++ 
129 V +++++ 
130 I +++++ + 
131 V +++++ 
132 I +++++ + 
134 I +++++ + 
135 I +++++ + 
136 I +++++ + 
137 I +++++ +++++ 
138 I +++++ ++ 
139 I +++++ + 
140 I +++++ +++ 
141 I +++++ ++ 
142 I +++++ +++ 
42 
Serum# Results* VP7n Peptide NS2 Peptide 
143 I +++++ ++++ 
144 I +++ ++ 
145 I +++ +++ 
146 I +++ +++++ 
147 I +++++ ++ 
148 I +++++ ++ 
149 I ++++ +++++ 
150 I ++++ +++ 
151 I ++++ ++ 
152 I ++ ++ 
153 I +++++ ++++ 
154 V +++ 
155 I +++++ +++ 
156 I ++++ +++++ 
157 V ++++ 
158 V ++++ 
159 V +++ 
160 V +++++ 
161 V +++++ 
162 V +++++ 
163 V +++++ 
164 V +++++ 
165 V +++++ 
166 V +++++ 
167 I +++++ ++ 
168 I +++++ ++ 
169 V +++++ 
170 I +++++ + 
171 I +++++ ++ 
172 I +++++ +++ 
173 I +++++ +++ 
174 I +++++ +++++ 
175 I +++++ +++++ 
176 I +++++ +++++ 
177 I +++++ + 
178 V +++ 
179 I ++ +++ 
180 V +++ 
181 I +++ +++++ 
182 I +++ +++ 
183 I ++++ + 
184 V +++++ 
185 I +++++ + 
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Serum# Results* VP7n Peptide NS2 Peptide 
186 V +++++ 
187 I +++++ + 
188 I +++++ +++++ 
190 I ++++ +++++ 
191 I ++ + 
193 V ++ 
195 I ++++ ++ 
196 I ++++ ++ 
197 I ++++ ++ 
199 I ++++ +++++ 
200 I ++++ +++++ 
201 I +++++ +++++ 
202 I ++++ +++++ 
203 I ++++ +++++ 
204 V ++++ 
205 V ++++ 
206 I ++++ + 
207 I ++++ + 
208 I ++ + 
210 V ++ 
211 V ++++ 
212 V ++++ 
213 V ++++ 
214 V ++++ 
215 V ++++ 
*!=infected, U=uninfected, V=vaccinated 
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Table 3. Results of 23 ovine sera testing using the BTV diagnostic assay 
Serum# Results* VP7n Peptide NS2 Peptide 
CT2040 V ++ 
YU1008 V +++ 
YU1009 V +++ 
YV1003 V ++++ 
YV1006 V ++++ 
YV1010 V ++++ 
YVlOll V ++++ 
YV1013 V ++++ 
YV1019 V ++++ 
YV1023 V ++++ 
YV1029 V +++ 
YV1031 V ++++ 
YV1041 V ++++ 
YV1042 V ++++ 
YV1043 V ++++ 
YV1045 V ++++ 
YV1047 V ++++ 
YV1053 V ++++ 
BA2009 V + 
BA2010 V ++ 
BA2011 V ++ 
BA2012 V ++ 
BA2013 V +++ 
*!=infected, U=uninfected, V=vaccinated 
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Table 4. Results of 5 bovine sera testing using the BTV diagnostic assay 
Serum# Results* VP7n Peptide NS2 Peptide 
BK2003 I +++ + 
BK2007 I +++ + 
BK2012 I +++ + 
BK2014 I +++ ++ 
BK2015 I +++ +++ 
*!=infected, U=uninfected, V=vaccinated 
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Table 5. Results of 18 caprine sera testing using the BTV diagnostic assay 
Serum# Results* VP7n Peptide NS2 Peptide 
BM2005 I ++ + 
BM2007 V ++ 
BM2018 V ++ 
BM2020 I ++ ++ 
BM2029 V +++ 
BM2030 V ++ 
BE2001 V + 
BE2011 V + 
BE2014 V + 
BE2018 V ++ 
BE2033 I +++ + 
BE2038 V +++ 
BE2041 V +++ 
BE2054 V +++ 
BE2055 I + +++++ 
BE2077 V +++ 
BE2078 I ++ +++++ 
BE2083 V ++ 
*!=infected, U=uninfected, V=vaccinated 
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Appendix B: Abbreviations 
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ABBREVIATIONS 
AP alkaline phosphatase 
ATP adenosine triphosphate 
BSA bovine serum albumin 
BTV 13 bluetongue virus serotype 13 
EDTA ethylenediaminetetraacetic acid 
PAGE polyacrylamide gel electrophoresis 
sos sodium dodecyl sulfate 
TEMED N,N,N,N tetramethylethylendiamine 
